Hot Pursuit     06-Feb-24
Biocon Ltd up for fifth session
Biocon Ltd is quoting at Rs 299.4, up 5.18% on the day as on 12:44 IST on the NSE. The stock is up 25.93% in last one year as compared to a 23.57% spurt in NIFTY and a 51.47% spurt in the Nifty Pharma.

Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 299.4, up 5.18% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.58% on the day, quoting at 21898.9. The Sensex is at 72148.53, up 0.58%. Biocon Ltd has risen around 6.72% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 7.39% in last one month and is currently quoting at 18292.95, up 0.95% on the day. The volume in the stock stood at 160.28 lakh shares today, compared to the daily average of 52.13 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 300, up 4.9% on the day. Biocon Ltd is up 25.93% in last one year as compared to a 23.57% spurt in NIFTY and a 51.47% spurt in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending September 23.

Previous News
  Biocon gets nod from SAHPRA for Tacrolimus capsules
 ( Hot Pursuit - 20-Apr-24   15:36 )
  Biocon Ltd spurts 4.01%, rises for fifth straight session
 ( Hot Pursuit - 26-Apr-24   13:00 )
  Biocon Ltd eases for fifth straight session
 ( Hot Pursuit - 12-Jul-24   13:36 )
  Biocon Biologics refinances debt through USD bonds and syndicated term loan
 ( Corporate News - 03-Oct-24   09:29 )
  Biocon 's biologics subsidiary gets European Commission's nod for Aflibercept biosimilar
 ( Hot Pursuit - 21-Sep-23   09:24 )
  Biocon Ltd up for third consecutive session
 ( Hot Pursuit - 29-Sep-23   13:05 )
  ICICI Bank board to mull fund raising proposal
 ( Hot Pursuit - 20-Apr-24   14:40 )
  Biocon Ltd up for fifth session
 ( Hot Pursuit - 06-Feb-24   13:00 )
  Biocon's subsidiary receives UK’s MHRA approval for Aflibercept biosimilar
 ( Hot Pursuit - 13-Nov-23   17:05 )
  Biocon
 ( Results - Analysis 16-Feb-23   10:55 )
  Biocon Biologics set to introduce YESAFILI®, a proposed biosimilar to EYLEA® in Canadian market
 ( Corporate News - 04-Mar-24   09:30 )
Other Stories
  BLS Intl Q3 PAT climbs 47% YoY to Rs 128 cr in FY25
  11-Feb-25   15:49
  Prince Pipes slumps after reporting dismal Q3 results
  11-Feb-25   15:30
  Crisil jumps after Q4 PAT rises 6.9% YoY
  11-Feb-25   15:24
  Northern Spirits spurts after Q3 PAT zooms 110% YoY to Rs 9 crore
  11-Feb-25   15:14
  Keystone Realtors Q3 PAT rises to Rs 30 cr in FY25
  11-Feb-25   15:10
  Talbros Automotive Q3 PAT rises 5% YoY to Rs 24 cr
  11-Feb-25   15:03
  HBL Engineering Ltd leads losers in 'A' group
  11-Feb-25   15:00
  Welspun Investments & Commercials Ltd leads losers in 'B' group
  11-Feb-25   14:45
  Volumes soar at CRISIL Ltd counter
  11-Feb-25   14:30
  Cera Sanitaryware declines as Q3 PAT slips 10% YoY to Rs 46 cr
  11-Feb-25   14:30
Back Top